UBS Group AG Sells 456,676 Shares of NeoGenomics, Inc. $NEO

UBS Group AG cut its position in NeoGenomics, Inc. (NASDAQ:NEO) by 56.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 347,574 shares of the medical research company’s stock after selling 456,676 shares during the period. UBS Group AG’s holdings in NeoGenomics were worth $4,087,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in NeoGenomics by 1.9% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 132,882 shares of the medical research company’s stock valued at $1,563,000 after purchasing an additional 2,414 shares during the period. First Horizon Corp boosted its stake in NeoGenomics by 52.6% in the 4th quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 865 shares during the period. CWM LLC boosted its stake in NeoGenomics by 19.4% in the 4th quarter. CWM LLC now owns 10,327 shares of the medical research company’s stock valued at $121,000 after purchasing an additional 1,677 shares during the period. State of Alaska Department of Revenue boosted its stake in NeoGenomics by 1.7% in the 4th quarter. State of Alaska Department of Revenue now owns 73,044 shares of the medical research company’s stock valued at $858,000 after purchasing an additional 1,215 shares during the period. Finally, Choreo LLC boosted its stake in NeoGenomics by 2.2% in the 4th quarter. Choreo LLC now owns 61,462 shares of the medical research company’s stock valued at $752,000 after purchasing an additional 1,313 shares during the period. 98.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on NEO. Piper Sandler boosted their price target on NeoGenomics from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, February 24th. Needham & Company LLC boosted their price target on NeoGenomics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. William Blair restated a “market perform” rating on shares of NeoGenomics in a research note on Monday, March 16th. Zacks Research downgraded NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 20th. Finally, UBS Group reiterated a “hold” rating on shares of NeoGenomics in a research report on Wednesday, February 18th. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $13.86.

NeoGenomics Stock Performance

NASDAQ:NEO opened at $9.23 on Friday. The stock has a fifty day moving average price of $8.27 and a 200-day moving average price of $10.30. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -11.99 and a beta of 1.81. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.06 and a current ratio of 4.42. NeoGenomics, Inc. has a fifty-two week low of $4.72 and a fifty-two week high of $13.74.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, April 28th. The medical research company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. The firm had revenue of $186.67 million during the quarter, compared to the consensus estimate of $184.54 million. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.NeoGenomics’s revenue was up 11.3% on a year-over-year basis. As a group, equities analysts anticipate that NeoGenomics, Inc. will post -0.15 EPS for the current fiscal year.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.